SG10202107832UA - Dosage regimen for treatment of solid tumors - Google Patents

Dosage regimen for treatment of solid tumors

Info

Publication number
SG10202107832UA
SG10202107832UA SG10202107832UA SG10202107832UA SG10202107832UA SG 10202107832U A SG10202107832U A SG 10202107832UA SG 10202107832U A SG10202107832U A SG 10202107832UA SG 10202107832U A SG10202107832U A SG 10202107832UA SG 10202107832U A SG10202107832U A SG 10202107832UA
Authority
SG
Singapore
Prior art keywords
treatment
solid tumors
dosage regimen
regimen
dosage
Prior art date
Application number
SG10202107832UA
Other languages
English (en)
Inventor
Karim Benhadji
Eunice Yuen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG10202107832UA publication Critical patent/SG10202107832UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10202107832UA 2016-08-31 2017-08-24 Dosage regimen for treatment of solid tumors SG10202107832UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662381911P 2016-08-31 2016-08-31

Publications (1)

Publication Number Publication Date
SG10202107832UA true SG10202107832UA (en) 2021-09-29

Family

ID=59772787

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201901325UA SG11201901325UA (en) 2016-08-31 2017-08-24 Dosage regimen for treatment of solid tumors
SG10202107832UA SG10202107832UA (en) 2016-08-31 2017-08-24 Dosage regimen for treatment of solid tumors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201901325UA SG11201901325UA (en) 2016-08-31 2017-08-24 Dosage regimen for treatment of solid tumors

Country Status (14)

Country Link
US (1) US20190209581A1 (pt)
EP (1) EP3506905B1 (pt)
JP (2) JP2019526632A (pt)
KR (1) KR102512899B1 (pt)
CN (2) CN116473978A (pt)
AU (1) AU2017321011B2 (pt)
BR (1) BR112019002461A2 (pt)
CA (1) CA3035616A1 (pt)
ES (1) ES2977556T3 (pt)
IL (2) IL264924B2 (pt)
MA (1) MA46086A (pt)
MX (1) MX2019002066A (pt)
SG (2) SG11201901325UA (pt)
WO (1) WO2018044662A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
ES2898952T3 (es) 2016-04-12 2022-03-09 Lilly Co Eli Terapia de combinación con inhibidores de Notch y PI3K/mTOR para su uso en el tratamiento del cáncer de ovario
KR102418765B1 (ko) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법
SG11201810268YA (en) 2016-05-20 2018-12-28 Lilly Co Eli Combination therapy with notch and pd-1 or pd-l1 inhibitors
US11376259B2 (en) 2016-10-12 2022-07-05 Eli Lilly And Company Targeted treatment of mature T-cell lymphoma
US11845803B2 (en) 2017-02-17 2023-12-19 Fred Hutchinson Cancer Center Combination therapies for treatment of BCMA-related cancers and autoimmune disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US46206A (en) 1865-02-07 Improved vessel for holding petroleum
WO2008112249A1 (en) * 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
EP3354276B1 (en) * 2007-11-13 2020-01-01 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
JO3148B1 (ar) 2011-07-27 2017-09-20 Lilly Co Eli مركب مثبط لإشارات مسار notch
JP2017526641A (ja) * 2014-07-11 2017-09-14 ジェネンテック, インコーポレイテッド Notch経路阻害
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療

Also Published As

Publication number Publication date
CN109562114A (zh) 2019-04-02
MX2019002066A (es) 2019-06-03
CN116473978A (zh) 2023-07-25
IL264924B1 (en) 2023-09-01
JP2019526632A (ja) 2019-09-19
AU2017321011B2 (en) 2023-08-03
AU2017321011A1 (en) 2019-02-21
MA46086A (fr) 2019-07-10
IL264924A (pt) 2019-04-30
ES2977556T3 (es) 2024-08-26
BR112019002461A2 (pt) 2019-05-14
CA3035616A1 (en) 2018-03-08
IL264924B2 (en) 2024-01-01
WO2018044662A1 (en) 2018-03-08
EP3506905A1 (en) 2019-07-10
KR20190042591A (ko) 2019-04-24
KR102512899B1 (ko) 2023-03-23
EP3506905B1 (en) 2024-03-20
SG11201901325UA (en) 2019-03-28
JP2023052108A (ja) 2023-04-11
IL305136A (en) 2023-10-01
US20190209581A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
HK1247202A1 (zh) 用於治療癌症的化合物
HK1258779A1 (zh) 用於治療癌症的作為btk抑制劑的吡唑並嘧啶衍生物
HK1247129A1 (zh) 治療癌症的聯合療法
LT3139925T (lt) Valbenazino dozavimo režimas, skirtas gydyti hiperkinetinio judėjimo sutrikimus
ZA201806819B (en) Pharmaceutical combinations for the treatment of cancer
HK1251475A1 (zh) 用於癌症治療的聯合療法
IL285077A (en) Compounds for the treatment of cancer
IL259996A (en) Combinations for cancer treatment
HK1254882A1 (zh) 用於治療癌症的組合療法
SG10202107832UA (en) Dosage regimen for treatment of solid tumors
ZA201900052B (en) Pharmaceutical combinations for treating cancer
IL259101A (en) Dosing regimens of malafone for cancer
HK1253098A1 (zh) 用於治療癌症的mdm2抑制劑的給藥方案
IL265762A (en) Dosing regimen of avolumab for cancer treatment
ZA201704589B (en) Compounds for the treatment of cancer
GB201614179D0 (en) Dosage regimen for the treatment of endometriosis
IL236381A0 (en) Pharmaceutical preparations for the treatment of cancer